Lyra Therapeutics, Inc. (LYRA)
LYRA moved a median of -0.02% 30 minutes after news, and -0.23% by the close. How LYRA actually reacts to news — the realized, point-in-time move the market made, measured across 155 labeled events over the last three years with zero look-ahead.
LYRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.09% | 35% | 152 |
| 30-min | -0.02% | 43% | 155 |
| 60-min | -0.19% | 39% | 155 |
| to close | -0.23% | 41% | 152 |
| Middle 50% of LYRA reactions | -2.60% to +1.05% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 155 |
Half of all Lyra Therapeutics, Inc. news events land between -2.60% and +1.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LYRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 13 | -2.09% | 31% | -4.54% |
| Rating reiterations | 25 | +1.74% | 80% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how LYRA ranks against every other measured name →
That’s how LYRA usually reacts — get an email when it moves on news →Email me when LYRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LYRA's baseline. Nothing else.
Recent LYRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Lyra Therapeutics, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +14.65% | +21.91% | |
| Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC | Press release | GlobeNewswire | +14.65% | +21.91% | |
| Form 8-K Lyra Therapeutics, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +13.21% | +22.64% | |
| Form 10-K Lyra Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.02% | |
| Form EFFECT Lyra Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -13.54% | -16.91% | |
| Form POS AM Lyra Therapeutics, Inc. | SEC filing · Form POS | SEC EDGAR | +0.00% | +0.04% | |
| Form S-8 POS Lyra Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.04% | |
| Form 8-K Lyra Therapeutics, Inc. For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +13.00% | +61.29% | |
| Form 8-K Lyra Therapeutics, Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | +22.68% | |
| Form 8-K Lyra Therapeutics, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -7.10% | -16.94% | |
| Form 8-K Lyra Therapeutics, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.00% | |
| Lyra Therapeutics Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +3.00% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.68% | — | |
| Form 8-K Lyra Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | — | |
| Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.68% | — | |
| Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study | Press release | GlobeNewswire | +6.94% | +8.30% | |
| Form 8-K Lyra Therapeutics, Inc. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | — | -3.03% | |
| Form 8-K Lyra Therapeutics, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -2.49% | -4.16% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +6.11% | |
| Form 8-K Lyra Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.11% | |
| Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +6.11% | |
| Form 8-K Lyra Therapeutics, Inc. For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | +0.74% | |
| Form EFFECT Lyra Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.44% | -4.29% | |
| Form S-1 Lyra Therapeutics, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.00% | +2.44% | |
| Form 8-K Lyra Therapeutics, Inc. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | -1.83% | |
| Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -3.32% | -5.60% | |
| Form 8-K Lyra Therapeutics, Inc. For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | +13.20% | |
| Form 8-K Lyra Therapeutics, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | -19.09% | |
| Form 8-K Lyra Therapeutics, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +7.41% | -30.17% | |
| Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) | Press release | GlobeNewswire | +7.41% | -30.17% | |
| Form 8-K Lyra Therapeutics, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +0.00% | |
| Form DEFA14A Lyra Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.84% | -3.88% | |
| Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 | Press release | GlobeNewswire | -0.09% | -4.11% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.09% | -4.11% | |
| Form 8-K Lyra Therapeutics, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -4.11% | |
| Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.09% | -4.11% | |
| Form DEF 14A Lyra Therapeutics, Inc. For: May 14 | SEC filing · Form DEF | SEC EDGAR | +0.37% | +12.50% | |
| Form DEFA14A Lyra Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.37% | +12.50% | |
| Form PRE 14A Lyra Therapeutics, Inc. For: May 14 | SEC filing · Form PRE | SEC EDGAR | -3.07% | -2.32% | |
| Form 10-K Lyra Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.59% | +0.88% | |
| Form 8-K Lyra Therapeutics, Inc. For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +0.88% | |
| Form S-8 Lyra Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.59% | +0.88% | |
| Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.59% | +0.88% | |
| Form 8-K Lyra Therapeutics, Inc. For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -1.46% | -2.50% | |
| Form 8-K Lyra Therapeutics, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +0.81% | |
| Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer | Press release | Business Wire | -2.88% | -4.02% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.21% | -25.40% | |
| Form 8-K Lyra Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | -25.40% | |
| Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.21% | -25.40% | |
| Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | Press release | GlobeNewswire | +2.81% | +2.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LYRA section they belong to.
Where else LYRA is measured.
LYRA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lyra Therapeutics, Inc.'s median reaction calculated?
Every labeled LYRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 155 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of LYRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LYRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.